The American Journal of Managed Care (12/23, Rath) reports, “Alopecia areata has a greater impact on the mental health and work-related outcomes of non-White individuals compared with White individuals, according to a study.” Investigators found that “Greater risks of depressive episodes…recurrent major depressive disorder…and anxiety disorders…were linked to alopecia areata.” The data indicated that “participants of Black ethnicity had elevated rates of alopecia areata–associated risk of anxiety disorders.” Meanwhile, “mental health risks linked to alopecia areata were observed in urban areas but not rural regions.” The findings were published in British Journal of Dermatology.

Related Links:

— “Alopecia Areata Linked to Mental Health, Socioeconomic, Racial Disparities,” Cameron Santoro, American Journal of Managed Care, December 23, 2024

HealthDay (12/20, Thompson ) reported a study suggests that “seniors with an infection can take antibiotics without fear of harming their brain health.” Antibiotics do not “appear to increase the risk of cognitive decline or dementia in older adults, researchers report.” One investigator said, “Given that older adults are more frequently prescribed antibiotics and are also at higher risk for cognitive decline, these findings offer reassurance about using these medications.” The findings were published in Neurology.

Related Links:

— “Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says,” Dennis Thompson, HealthDay, December 20, 2024

Bloomberg Law (12/20, Phengsitthy , Subscription Publication) reported, “The US government is going after drugmakers such as Bristol Myers Squibb Co., Johnson & Johnson, and Merck & Co. to pay rebates to Medicare if they raise the price of some of their drugs faster than inflation beginning in January.” A number of “Medicare enrollees will pay a lower coinsurance rate for 64 drugs treating cancer, osteoporosis, and substance use disorder between Jan. 1 and March 31, 2025, the US Department of Health and Human Services said Friday.” According to HHS, “over 853,000 people with Medicare use these drugs annually.” Beneficiaries who take these drugs “in the first quarter of 2025 may save between $1 and $10,818 per day, according to the agency.”

Related Links:

— “Medicare Imposes Savings on 64 Drugs Exceeding Inflation Rate,” Nyah Phengsitthy, Bloomberg Law, December 20, 2024

HealthLeaders Media (12/19, Wicklund ) reports, “Federal officials have launched a new behavioral health program aimed at creating care management programs for Medicare and Medicaid patients dealing with severe mental health conditions and substance abuse disorder (SUD).” The CMS “Innovation in Behavioral Health (IBH) Model seeks to bridge the gap between behavioral health and primary care by enabling specialty behavioral health practices, including community mental health centers, opioid treatment programs and private or public practices, to create interprofessional care teams to coordinate care.” The new program’s goal “is to improve care and outcomes for the estimated 25% of all Medicare patients experiencing mental illness and the 40% of Medicaid patients dealing with a mental illness or SUD.”

Related Links:

— “CMS LAUNCHES NEW PROGRAM FOR MENTAL HEALTH, OUD TREATMENT,” Eric Wickland, HealthLeaders Media, December19 , 2024

HealthDay (12/19, Thompson ) reports, “Teenagers who land in an ER with a mental health crisis can be effectively helped by a community-based program.” A new study “shows that troubled teens placed in such a program were significantly less likely to return to the ER or require inpatient psychiatric care due to a follow-up crisis.” The community-based “program did not reduce risk of a subsequent suicide attempt, but did reduce the risk of being hospitalized for a suicide attempt.” The findings were published in Psychiatric Services.

Related Links:

— “New Youth Mental Health Program Shows Promise,” Dennis Thompson, HealthDay, December 19, 2024